Serina Says Panel Clears Dosing More Patients in Phase 1b Trial of SER-252 in Parkinson's Disease

MT Newswires Live

07/10

Serina Therapeutics (SER) said Thursday the independent safety monitoring committee for its phase 1b trial of SER-252 in patients with advanced Parkinson's disease recommended dosing additional patients after a review of the initial 72-hour safety and tolerability data from the sentinel dosing group.

The company said additional patient dosing in cohort 1 of the study is now taking place at clinical sites in the US and Australia.

Serina said it now expects to complete enrollment and dosing of cohort 1 ahead of its previous guidance to finish by the end of Q3.

SER 252 is an investigational apomorphine therapy developed with Serina's POZ platform and designed to provide continuous dopaminergic stimulation, which has been known to reduce the severity of levodopa-related motor complications in Parkinson's disease, the company said.

Shares of Serina Therapeutics rose more than 9% in Thursday trading.

Price: 2.19, Change: +0.19, Percent Change: +9.50

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2650754409"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2650754409\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2650754409?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 00:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650754409","market":"sh","top_or_hot":-1,"title":"Serina Says Panel Clears Dosing More Patients in Phase 1b Trial of SER-252 in Parkinson's Disease","media":"MT Newswires Live","content":"<html><body><p> Serina <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (SER) said Thursday the independent safety monitoring committee for its phase 1b trial of SER-252 in patients with advanced Parkinson's disease recommended dosing additional patients after a review of the initial 72-hour safety and tolerability data from the sentinel dosing group.</p><p>The company said additional patient dosing in cohort 1 of the study is now taking place at clinical sites in the US and Australia.</p><p>Serina said it now expects to complete enrollment and dosing of cohort 1 ahead of its previous guidance to finish by the end of Q3.</p><p>SER 252 is an investigational apomorphine therapy developed with Serina's POZ platform and designed to provide continuous dopaminergic stimulation, which has been known to reduce the severity of levodopa-related motor complications in Parkinson's disease, the company said.</p><p>Shares of Serina Therapeutics rose more than 9% in Thursday trading.</p><p>Price: 2.19, Change: +0.19, Percent Change: +9.50</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Serina Says Panel Clears Dosing More Patients in Phase 1b Trial of SER-252 in Parkinson's Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSerina Says Panel Clears Dosing More Patients in Phase 1b Trial of SER-252 in Parkinson's Disease\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-07-10 00:40</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Serina <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (SER) said Thursday the independent safety monitoring committee for its phase 1b trial of SER-252 in patients with advanced Parkinson's disease recommended dosing additional patients after a review of the initial 72-hour safety and tolerability data from the sentinel dosing group.</p><p>The company said additional patient dosing in cohort 1 of the study is now taking place at clinical sites in the US and Australia.</p><p>Serina said it now expects to complete enrollment and dosing of cohort 1 ahead of its previous guidance to finish by the end of Q3.</p><p>SER 252 is an investigational apomorphine therapy developed with Serina's POZ platform and designed to provide continuous dopaminergic stimulation, which has been known to reduce the severity of levodopa-related motor complications in Parkinson's disease, the company said.</p><p>Shares of Serina Therapeutics rose more than 9% in Thursday trading.</p><p>Price: 2.19, Change: +0.19, Percent Change: +9.50</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SER.AU","symbol_name":"STRATEGIC ENERGY RESOURCES","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2650754409","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2650754409","pubTimestamp":1783615201,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Serina Therapeutics  said Thursday the independent safety monitoring committee for its phase 1b trial of SER-252 in patients with advanced Parkinson's disease recommended dosing additional patients after a review of the initial 72-hour safety and tolerability data from the sentinel dosing group.The company said additional patient dosing in cohort 1 of the study is now taking place at clinical sites in the US and Australia.Serina said it now expects to complete enrollment and dosing of cohort 1 ahead of its previous guidance to finish by the end of Q3.SER 252 is an investigational apomorphine therapy developed with Serina's POZ platform and designed to provide continuous dopaminergic stimulation, which has been known to reduce the severity of levodopa-related motor complications in Parkinson's disease, the company said.Shares of Serina Therapeutics rose more than 9% in Thursday trading.Price: 2.19, Change: +0.19, Percent Change: +9.50","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SER.AU":"STRATEGIC ENERGY RESOURCES","SER":"Serina Therapeutics, Inc.","BK4139":"生物科技","BK7095":"多种金属与采矿"},"translate_title":"Serina 表示，专家组批准在 SER-252 治疗帕金森病的 1b 期试验中给更多患者注射剂量","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SER":1.5,"SER.AU":1},"content_text":"Serina Therapeutics (SER) said Thursday the independent safety monitoring committee for its phase 1b trial of SER-252 in patients with advanced Parkinson's disease recommended dosing additional patients after a review of the initial 72-hour safety and tolerability data from the sentinel dosing group.The company said additional patient dosing in cohort 1 of the study is now taking place at clinical sites in the US and Australia.Serina said it now expects to complete enrollment and dosing of cohort 1 ahead of its previous guidance to finish by the end of Q3.SER 252 is an investigational apomorphine therapy developed with Serina's POZ platform and designed to provide continuous dopaminergic stimulation, which has been known to reduce the severity of levodopa-related motor complications in Parkinson's disease, the company said.Shares of Serina Therapeutics rose more than 9% in Thursday trading.Price: 2.19, Change: +0.19, Percent Change: +9.50","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}